Clinical Trials Logo

P13K-AKT Pathway Deregulation clinical trials

View clinical trials related to P13K-AKT Pathway Deregulation.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT01789060 Completed - Malignant Lymphoma Clinical Trials

p-AKT Expression on Clinical Outcomes in Malignant Lymphoma

Start date: December 2012
Phase: N/A
Study type: Observational

PI3K(phosphatidylinositol 3-kinase)/AKT pathway is an important oncogenic signaling pathway. However, clinical information about the significance of p-AKT expression in malignant lymphoma is not fully understood yet. In this study, we investigated the overexpression of p-AKT and its prognostic implication in malignant lymphoma.